Mednet Logo

Do children with intermediate-risk Burkitt lymphoma benefit from adding rituximab?

Community PollStarted

Do you use Rituximab for patients with intermediate risk Burkitt's Lymphoma?

1 physician has voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Toronto
Answered on

The answer is yes. The randomization to addition of Rituximab in the recently closed international study was done in intermediate risk patients with high LDH (Minard-Colin et al., PMID 32492302) The trial was stopped early because of the clear advantage in the Rituximab arm. The only patients not st...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Pediatric Hematology/Oncology · University of Colorado School of Medicine - Anschutz Medical Campus
Answered on

Just to clarify, Group B patients with normal LDH were not included in the randomized trial as they have a 95% EFS without rituximab.

Join for free or sign in to see the full answer